Combo Therapy for Psoriasis With Obesity
A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
By
Kathryn Wighton
February 18, 2026
Clinical Scorecard: Combo Therapy for Psoriasis With Obesity
At a Glance
Category Detail
Condition Moderate-to-severe plaque psoriasis with obesity Key Mechanisms Ixekizumab targets interleukin 17A; Tirzepatide acts as a dual GLP-1 and GIP receptor agonist. Target Population Adults with moderate-to-severe plaque psoriasis and obesity (BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidity) Care Setting Outpatient, randomized clinical trial
Key Highlights
27% of patients achieved complete skin clearance and at least 10% weight loss with ixekizumab plus tirzepatide at 36 weeks. 41% of the combination therapy group achieved Psoriasis Area and Severity Index 100 compared to 29% in the monotherapy group. The study enrolled 274 patients with a mean BMI greater than 39 kg/m². Guideline-Based Recommendations
Diagnosis
Diagnosis of moderate-to-severe plaque psoriasis based on clinical assessment and severity scoring. Management
Consider ixekizumab in combination with tirzepatide for patients with obesity and moderate-to-severe plaque psoriasis. Monitoring & Follow-up
Monitor for adverse events and treatment efficacy at regular intervals. Risks
Mild to moderate adverse events including nausea, diarrhea, and injection site reactions. Patient & Prescribing Data
Adults with moderate-to-severe plaque psoriasis and obesity.
Counseling on a reduced-calorie diet and increased physical activity is recommended alongside pharmacotherapy.
Clinical Best Practices
Assess BMI and comorbidities before initiating treatment. Provide lifestyle modification counseling to enhance treatment outcomes. References
